Nimotop (Nimodipine)

Nimotop (nimodipine) is indicated for conditions involving cerebral vasospasm and other cerebrovascular disorders.

• Subarachnoid hemorrhage (post‑aneurysmal): prevents delayed cerebral vasospasm and reduces risk of secondary ischemic injury.
• Cerebral vasospasm (any etiology): induces vasodilation to improve cerebral blood flow and mitigate neurological deficits.
• Cerebrovascular disorders (e.g., ischemic stroke adjunct): supports perfusion in affected brain regions as part of comprehensive therapy.

• Nimodipine selectively blocks L‑type voltage‑gated calcium channels predominantly in the smooth muscle of cerebral arteries. By inhibiting calcium influx, it relaxes vascular smooth muscle, producing vasodilation that enhances cerebral blood flow without markedly affecting systemic blood pressure. This targeted action helps counteract the narrowing of cerebral vessels that occurs after subarachnoid hemorrhage and in other neurovascular pathologies.

Nimotop may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache
• Flushing
• Nausea or vomiting
• Dizziness or light‑headedness

Serious or Rare Side Effects

• Severe hypotension
• Cardiac arrhythmias
• Hepatic dysfunction (elevated transaminases)

When prescribing Nimotop, clinicians should consider several safety considerations to minimize risk.

• Indication verification: ensure use is limited to approved neurovascular conditions such as post‑hemorrhagic vasospasm.
• Cardiovascular monitoring: observe blood pressure and heart rate, especially in patients with pre‑existing hypotension.
• Hepatic function: assess liver enzymes before initiation and periodically during therapy.
• Drug interactions: review concomitant medications that affect calcium channel activity or hepatic metabolism.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Nimotop can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nimodipine plasma levels and risk of toxicity.
• Concurrent use with other potent vasodilators (e.g., nitroglycerin): can cause additive hypotensive effects.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic concentrations.
• Beta‑blockers or other antihypertensives: require blood pressure monitoring to avoid excessive lowering.
• Antacids containing aluminum or magnesium: may affect absorption; separate administration by at least 2 hours.